Search the Newsreel

Net income before discontinued operations of Sionna Therapeutics, Inc. – BMV:SION

SION Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Sionna Therapeutics, Inc. (SION), based on analyst opinions. It details maximum and minimum price estimates, upcoming earnings reports, historical financial data such as EPS, revenue, and net income, and confirms that SION does not pay …

Raymond James Initiates Sionna Therapeutics(SION.US) With Hold Rating

Raymond James has initiated coverage on Sionna Therapeutics (SION.US) with a Hold rating. This indicates a neutral stance on the stock by the brokerage firm.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sionna Therapeutics, Inc. (SION) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Sionna Therapeutics, Inc. (SION) following a significant drop in its stock price. This comes after Sionna reported a primary endpoint miss in its PreciSION CF Phase 2a trial and announced it would not advance …

Sionna (SION) Earnings Reading: Profit Per Share Clears Its Benchmark in the Latest Reading; Price Move

Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

Robbins Geller Rudman & Dowd LLP has launched an investigation into potential violations of U.S. federal securities laws by Sionna Therapeutics, Inc. (NASDAQ: SION). This follows an announcement by Sionna Therapeutics on August 10, 2026, that its SION-719 Phase 2a trial did not meet …

Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics

Robbins LLP, a shareholder rights law firm, is investigating Sionna Therapeutics (NASDAQ: SION) following a 92% stock drop. The investigation comes after the company reported disappointing results from its Phase 2a study of SION-719 for cystic fibrosis, failing to meet its key activity endpoint. …

Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky

Levi & Korsinsky, LLP has announced a securities investigation into Sionna Therapeutics (NASDAQ: SION) following a significant 92% drop in its share price. This decline occurred after the company revealed that its Phase 2a PreciSION CF trial for SION-719 failed to meet its primary …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sionna Therapeutics, Inc. (SION) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Sionna Therapeutics, Inc. (SION) following a significant drop in its stock price. The investigation stems from Sionna's August 10, 2026, announcement of topline data from its PreciSION CF Phase 2a trial, which included a …

Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP has initiated a securities fraud investigation into Sionna Therapeutics, Inc. (SION) following a significant stock drop. The investigation comes after Sionna announced a primary endpoint miss in its PreciSION CF Phase 2a trial and decided not to advance …

SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS) has initiated an investigation into Sionna Therapeutics, Inc. (NASDAQ: SION) for potential securities law violations. This investigation follows a significant drop in Sionna's share price after its SION-719 Phase 2a trial failed to meet its primary endpoint of …

Sionna Therapeutics (NASDAQ:SION) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen downgraded Sionna Therapeutics (NASDAQ:SION) to a "strong sell" rating. This comes amidst broader analyst sentiment leaning towards "hold," with the stock opening significantly below its 52-week high and reporting a quarterly loss that missed estimates. Insider selling has occurred, though some …

Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?

Is Sionna Therapeutics (SION) Undervalued After SION 719 Failed And Development Was Halted?

Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed?

Sionna Therapeutics (SION) experienced an 86.8% stock drop after discontinuing its lead cystic fibrosis candidate, SION-719, due to failing a Phase 2a trial. The company is now refocusing its pipeline on the SION-451 plus SION-2222 combination, aiming to preserve its US$268.30 million cash balance. …

SION ALERT: Investigation Launched into Sionna Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

Robbins Geller Rudman & Dowd LLP has initiated an investigation into Sionna Therapeutics, Inc. (NASDAQ: SION) following a significant drop in its stock price. The investigation stems from the company's announcement on August 10, 2026, that its SION-719 Phase 2a trial failed to meet …

Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says

Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provide a net positive risk-reward profile for the company, RBC Capital Markets said in a Wednesday note.The company is expected to present results from its phase 1 study of VX-828 in Silver …

Sionna Therapeutics (NASDAQ:SION) Lowered to Hold Rating by JonesTrading

JonesTrading has downgraded Sionna Therapeutics (NASDAQ:SION) from a "strong buy" to a "hold" rating following the failure of its lead cystic fibrosis drug, SION-719, to meet its primary endpoint in a Phase 2 trial. This setback led to a significant stock price drop and …

Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall

SION Q2 2026 Earnings: Narrower $0.66 Loss Drives 16.4% Jump in Shares - Financial Summary

One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses

Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASDAQ:VRTX), the company whose drug dominance Sionna was …

Why Sionna Therapeutics (SION) Is Down 90.9% After Ending SION-719 Add-On To Trikafta Therapy

Sionna Therapeutics, Inc. - Common Stock (SION) Stock Price, News, Quote & History

Sionna Therapeutics (SION) halted development of SION-719 after its Phase 2a study failed to meet the key activity endpoint for cystic fibrosis treatment, despite initially showing promise. The company is now focusing on the SION-451 combination path. This news follows previous reports on financial …

SION Stock Slides, Then Snaps Back As Traders Eye Volatility

Sionna Therapeutics Inc. (SION) stock experienced significant volatility, plunging from mid-$50s to around $5 before bouncing back intraday. Despite burning cash, the company boasts a strong balance sheet with $211.0M in cash and low debt, providing a substantial runway for its early-stage biotech strategy. …

Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results—Johnson Fistel Investigates

Johnson Fistel, PLLP is investigating Sionna Therapeutics, Inc. (SION) for potential violations of federal securities laws after the company's shares plummeted following disappointing Phase 2a clinical trial results for SION-719. The trial failed to show meaningful improvement in cystic fibrosis, leading Sionna to halt …

Sionna Therapeutics stock falls 92% after SION-719 trial failure

Sionna Therapeutics experienced a 92% stock drop after its experimental cystic fibrosis drug, SION-719, failed to meet its key endpoint in a Phase 2a trial. The company will not advance SION-719 as an add-on therapy and is evaluating its SION-451 program, while considering workforce …

SIONNA THERAPEUTICS, INC. : WEDBUSH CUTS TO NEUTRAL FROM OUTPERFORM; CUTS TARGET PRICE TO $5 FROM $53

Wedbush has downgraded Sionna Therapeutics Inc. (SION.O) from Outperform to Neutral and significantly cut its target price from $53 to $5. This revision reflects a more cautious outlook from the analyst firm regarding the biopharmaceutical company's prospects.

BTIG Downgrades Sionna Therapeutics to Neutral From Buy

Sionna Therapeutics (SION) Halts Lead Cystic Fibrosis Drug After Phase 2 Failure

Sionna Therapeutics (SION) has stopped development of its lead cystic fibrosis drug candidate after it failed a Phase 2 trial. This setback removes a key near-term catalyst for the company and shifts its focus to earlier-stage pipeline programs, increasing the importance of its remaining …

Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path

Sionna Therapeutics (NASDAQ:SION) Sets New 1-Year Low After Analyst Downgrade

Sionna Therapeutics, Inc. Common Stock (NASDAQ: SION) Stock Price, News & Analysis

Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low

Sionna Therapeutics stock crashed 91% after its experimental cystic fibrosis treatment, SION-719, failed to meet its key endpoint in a Phase 2a trial. The drug candidate did not show a meaningful reduction in sweat chloride levels, leading the company to shelve the highly anticipated …